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Hodgkin lymphoma (HL) demonstrates heterogenous histologic ﬁndings, clinical presentation, and outcomes. Using the United
States Surveillance, Epidemiology, and End Results (SEER) data we examined relationships between patient characteristics, clinical
features at diagnosis, and survival in HL patients. From 2000 to 2007, 16,710 cases were recorded in 17 SEER registries. Blacks and
Asians had low incidence (black/white incidence rate ratio (IRR) 0.86, P<. 01; Asian/white IRR 0.43, P<. 01). The bimodal
pattern of incidence was less prominent for black males. Asians and Blacks presented at a mean age of 38 years compared to 42
years for Whites (P<. 001). Race was a predictor for survival with HR of 1.19 (95% CI 1.11–1.28) for Blacks. Age was the most
important predictor of survival (HR for patients ≥45 years 5.08, 95% CI 4.86–5.31). These current patterns for presentation and
outcomes of HL help to delineate key populations in order to explore risk factors for HL and strategies to improve treatment
outcomes.
1.Introduction
Hodgkinlymphoma(HL)isacancerofthelymphaticsystem
commonly characterized by the presence of large malignant
lymphoid cells, Reed-Sternberg cells, although malignant
cells typically account for less than 1% of cells in the aﬀected
tissue [1]. The variable quantity and quality of the malignant
cells and the host response make the histologic ﬁndings in
HLheterogenous[2].IntheUnitedStates(US),anestimated
8,490 new cases were diagnosed with HL while HL was
accountable for 1,320 deaths in 2010 [3]. In the 1960s, the
5-year survival rate for HL was less than 10% [4]. With
breakthroughs in combination chemotherapy regimens, the
reported 5-year survival for patients with HL during the
years 2000–2004 was 85.2% [5]. However, relatively little is
known regarding the clinical and demographic factors that
inﬂuence the patterns of presentation and outcomes for HL
in a population-based setting in the US.
Recent epidemiological studies have found independent
associations between age, gender, race, geographic location,
and incidence of HL [2]. For example, Asians have been
shown to have a dramatically lower HL incidence than
other races, but even among US Asians there are signiﬁcant
incidence rate diﬀerences between US-born Asians versus
native Asians [6]. The incidence variation by age, geographic
location, social class, and time suggests an etiologic role for
infectious agents, such as Epstein-Barr virus (EBV), while
aggregation in families and persons with speciﬁc human
leukocyte antigen (HLA) types indicates genetic susceptibil-
ity [2, 7]. These and other factors inﬂuencing HL incidence
and outcomes are reviewed elsewhere in this journal [7].
To examine the relationships between demographic patient
characteristics, clinical features at diagnosis, and survival
outcomes in a national cohort of patients with HL, we
performed a retrospective analysis of HL cases diagnosed
from 1973 to 2007 reported to population-based cancer
registries.
2. Methods
2.1. Data Sources. We obtained population-based cancer
incidence data from the United States Surveillance, Epidemi-
ology, and End Results (SEER) Program. This database has
compiled incidence data since 1973 from nine population-
based registries (Connecticut, Hawaii, Iowa, New Mexico,2 Advances in Hematology
Utah, Detroit, San Francisco/Oakland, Seattle/Puget Sound,
and Atlanta), accounting for 10% of the United States popu-
lation [8]. The SEER 9 registries population is comparable to
thegeneralpopulationexceptcontainingahigherproportion
of urban areas and foreign-born persons [9]. In 1992, SEER
expanded to include two additional metropolitan areas (Los
Angeles County and San Jose/Monterey, California), Rural
Georgia, and the Alaska Native Tumor Registry, together
accounting for approximately 14% of the United States
population [10, 11]. Later in 2000, SEER included Greater
California, Kentucky, Louisiana, and New Jersey registries to
account for 26% of the US population [12]. For the analyses
of incidence rates, we used the SEER17 data compiled of
cases diagnosed from January 1, 2000 to December 31,
2007 [12]. Given its longer duration of followup, for the
survival analysis, we used the SEER9 data compiled of cases
diagnosed from January 1, 1973 to December 31, 2007
[7].
2.2. Study Cohort. The classiﬁcation of lymphoid neoplasms
has undergone several updates since the 1940s. Lymphomas
diagnosed from 1973 through 1977 were classiﬁed according
to the Manual of Tumor Nomenclature and Coding [13].
Then in 1978, the International Classiﬁcation of Diseases
for Oncology (ICD-O) [14]w a sa d o p t e dt oc o d ea l lc a n -
cers registered by the SEER Program. In 1992, the SEER
Program adopted the ICD-O, 2nd Edition (ICD-O-2) to
code lymphomas [15]. In 2001, the World Health Orga-
nization (WHO) classiﬁcation was introduced building on
the Revised European-American Lymphoma classiﬁcation
and the French-American-British classiﬁcation [16, 17]a n d
updated in 2008 [18]. Recently the United States cancer
registries adopted the ICD-O-3 with the ability to convert
cases coded in ICD-O-2 to ICD-O-3 [19] making it fea-
sible to assess incidence patterns and trends for lymphoid
neoplasmsaccordingtotheinternationallyrecognizedWHO
classiﬁcation [20].
We identiﬁed and categorized HL cases using the third
edition of the International Classiﬁcation of Diseases for
Oncology (ICD-O-3) [21] into classical HL (CHL) and
nodularlymphocytepredominantHL(NLP,ICD-O-39659).
CHL cases were further divided into the following subtypes:
lymphocyte-rich (LR, 9651), mixed cellularity (MC, 9652),
lymphocyte-depleted (LD, 9653–9655), nodular sclerosis
(NS, 9663–9667), and not-otherwise-speciﬁed (NOS, 9650–
9651) (Table 1). This corresponds with the InterLymph
clustering of the WHO classiﬁcation of lymphoid malignan-
cies into categories designed for lymphoma epidemiological
research [22]. All data refer to the incidence of neoplasms
with malignant behavior. The selection of HL cases for
analysis of incidence and survival is depicted in Figures 1(a)
and 1(b), respectively. Cases with unknown or unspeciﬁed
race were excluded from the analysis. Cases with known
race were grouped into white, black, American Indians or
Alaska Natives (AI/ANs), and Asians or Paciﬁc Islanders
(A/PIs). The SEER program records race as assigned by the
North American Association of Central Cancer Registries
[23]. Race and ethnicity were deﬁned by speciﬁc physical,
hereditary, and cultural traditions or origins, not necessarily
by birthplace, place of residence, or citizenship. Examination
of Hispanic ethnicity was beyond the scope of this study
because ethnicity was not recorded reliably in the SEER
registries during this time period [24].
SEER data were used to calculate survival time using the
dateofdiagnosisandoneofthefollowing:dateofdeath,date
last known to be alive, or date of the study cutoﬀ (December
31, 2007). For survival analyses, patients whose disease status
was based on a death certiﬁcate or autopsy only, patients
with second or later primaries, and patients who were not
actively followed were excluded, resulting in a cohort of
(23,292) cases. To evaluate the impact of modern therapies
onsurvival,wedividedpatientsintoerasbyyearofdiagnosis:
1973–1979, 1980–1989, 1990–1999, and 2000–2007.
2.3. Calculation and Presentation of Rates. Incidence rates
were expressed as new cases per 100,000 person-years and
age-adjusted to the 2000 U.S. standard population [25].
Incidence rates were compared by sex and race using
incidence rate ratios (IRRs) and 95% conﬁdence intervals
(95%CIs).Diﬀerencesinbaselinecharacteristicsatdiagnosis
across racial groups were analyzed using two-sided t-tests
and chi-square tests.
Two-yearandﬁve-yearrelativesurvivalrates(RSRs)were
calculated by actuarial methods, where relative survival is
deﬁned as the ratio of the proportion of observed survivors
in a cohort of cancer patients to the proportion of expected
survivors in a comparable set of cancer-free individuals, thus
representing survival in the absence of other causes of death.
A Z-test was used to test the equivalence of RSRs [26].
Survival curves were constructed using the Kaplan-Meier
method and compared with the log-rank test. Univariate
and multiple variable Cox proportional hazards models were
used to examine the covariates age at diagnosis, gender, race,
stage of disease, presence of extranodal disease, and presence
of B-symptoms as predictors of mortality.
A level of signiﬁcance (α) of .05 was considered sta-
tistically signiﬁcant. All statistics were computed using the
National Cancer Institute SEER∗Stat software, version 6.5.2.
(http://www.seer.cancer.gov/seerstat/), SAS software, version
9.0 (SAS Institute Inc. Copyright c 2002), and STATA 9.2
(StataCorp LP. Copyright c 1855–2006).
3. Results
3.1. Incidence of HL. During the period from 2000 to
2007, 16,710 cases of HL were diagnosed and reported
to the 17SEER registries. Of these, 161 cases with
unknown/unspeciﬁed racewereexcluded resulting in astudy
cohortof16,549cases:14,076whites,1,693blacks,58AI/AN,
and 722A/PI. The study populations for the incidence and
survival analyses are shown in Figure 1. The age-adjusted
incidence rate for HL was 2.74 (95% CI 2.69–2.78), NLP
was 0.11 (95% CI 0.1–0.12), and for CHL was 2.63 (95%
CI 2.59–2.67). The age-adjusted incidence rates for the CHL
subtypes LR, MC, LD, NS, and CHLNOS were 0.08 (95%Advances in Hematology 3
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Identiﬁed patients with
Hodgkin lymphoma diagnosed between
2000 –2007, in SEER 17 registries (n = 16710)
Excluded patients with unknown age at
diagnosis and unknown race (n = 16549)
Unknown age at diagnosis (n = 0)
Unknown/unspeciﬁed race (n = 161)
(a)
Identiﬁed patients with
Hodgkin lymphoma diagnosed between
1973 –2007, in SEER 9 registries(n = 24715)
Excluded patients with unknown age at
diagnosis and unknown race (n = 24583)
Excluded patients with missing
follow-up (n = 24418)
Unknown age at diagnosis (n = 0)
Unknown/unspeciﬁed race (n = 132)
Excluded second or later primaries
(n = 23292)
Missing follow-up (n = 165)
Second or later primaries (n = 1126)
(b)
Figure 1: Selection of study cohort. These ﬁgures provide an overview of the study cohort with reasons for inclusion/exclusion through the
selection process. (a) Selection of the cases included in the incidence analyses. (b) Selection of the cases included in the survival analyses.
CI 0.07–0.09), 0.37 (95% CI 0.35–0.39), 0.04 (95% CI 0.03–
0.04),1.63(95%CI1.59–1.66),and0.51(95%CI0.49–0.53),
respectively (Table 1).
3.2. Incidence Rates by Sex and Race. Males had signiﬁcantly
higher incidence rates than females for all HL subtypes. The
male-to-female (M/F) IRR was 1.27 (95% CI 1.23–1.31) for
allHLcombinedandgreatestforNLPHL(2.45, 95%CI 2.1–
2.9). Male predominance among HL was most pronounced
among A/PI (M/F IRR 1.35, 95% CI 1.2–1.6). Although the
overall incidence rates for HL were signiﬁcantly lower for
black patients than white patients (black-to-white IRR 0.86,
P<. 01), black patients had higher incidence rates compared
to white patients for NLP HL (black-to-white IRR 1.9, P<
.01; Table 1). The diﬀerence in incidence between whites and
Asians was even more prominent (Asian-to-white IRR 0.43,
P<. 01).
3.3. Age-Speciﬁc Incidence Rates. The age distribution of
CHL across gender and race diﬀered. White patients demon-
strated a bimodal distribution with prominent peaks at age
21–30 and >70 years, although the second peak for white
females was less prominent (Figure 2(a)). This bimodal age
distribution pattern was seen in all groups except for black
males with CHL. For NLP HL, however, the only obvious
bimodal incidence pattern was seen for black males, with
peak incidence rates at 31–40 years and 51–60 years.
3.4. Baseline Characteristics at Diagnosis. The baseline char-
acteristics at diagnosis by race are compared in Table 2.T h e
mean age at diagnosis for black patients and Asian/PI was
youngerthanthatforwhitepatients (both P<. 001;Table 2).
Blacks had a higher percentage of cases with an extranodal
disease (27% versus 23%, P<. 001), but no signiﬁcant
diﬀerence in the percentage of patients with B symptoms
(36% versus 35%, P = .058) compared to white patients.
Compared to white patients, black patients had a higher
percentage of cases diagnosed with stage III/IV disease (43%
versus 35%, P<. 001). Asian/PI patients also had a slightly
higher percentage of cases with stage III/IV HL (38% versus
35%, P<. 001). Information on stage, extranodal disease,
and B-symptoms was missing in 5.7%, 5.7%, and 24% of
cases, respectively.
3.5. Survival Analysis. The 2-year and 5-year RSRs for the
entire population of patients HL were 87% and 80%. The
2-year RSRs for CHL subtypes NS; LR; MC; LD; CHL,
NOS; NLP HL were 92%, 93%, 81%, 49%, 75%, and 97%,
respectively. The 5-year RSRs for CHL subtypes NS; LR; MC;
LD; CHL, NOS; NLP HL were 86%, 87%, 73%, 43%, 68%,
and 94%, respectively. Female patients had better RSRs than
males (2-year RSR: 88% versus 86%, 5-year RSR: 83% versus
78%, both P<. 001). White, black, and A/PI patients had
similarsurvivalrates(2-yearRSR:87%,85%,and84%,resp.,
5-year RSR: 81%, 77%, and 77%, resp., P<. 01). However,
race was a signiﬁcant predictor of survival in Cox regressionAdvances in Hematology 5
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Figure 2: Age distribution of HL by race. (a) Plots are the race- and gender-speciﬁc age-adjusted incidence rates of CHL by age at diagnosis.
(b) Plots are the race- and gender-speciﬁc age-adjusted incidence rates of NLP HL by age at diagnosis. (c) Plots are the age distribution of
CHL patients. Horizontal axis represents the grouping of age at diagnosis. Vertical axis represents the proportion of patients in each age
group for that particular race (White, Black, and Asian/Paciﬁc Islander). (d) Plots are the age distribution of NLP HL patients. Horizontal
axis represents the grouping of age at diagnosis. Vertical axis represents the proportion of patients in each age group for that particular race
(White, Black, and Asian/Paciﬁc Islander).
models (Table 3). In multiple variable Cox regression mod-
els, the most signiﬁcant predictors of survival were age ≥45
(HR 4.82, 95% CI 4.40–5.29), B symptoms (HR 1.82, 95%
CI 1.66–2.00), black race (HR 1.54, 95% CI 1.35–1.76), stage
IV disease (HR 1.29, 95% CI 1.05–1.59), and male gender
(HR 1.17, 95% CI 1.07–1.28; Table 3). Multiple variable Cox
regression models demonstrated that when compared to NS
HL, MC HL, LD HL, and CHL, NOS had worse survival with
HR of 1.31 (95% CI 1.17–1.46), 2.02 (95% CI 1.58–2.57),
and 1.65 (95% CI 1.46–1.86), respectively (Table 3).
There was a statistically signiﬁcant improvement in
survival across consecutive diagnostic eras (log-rank test P<
.001,Figure 3(c))withsimilartrendsobservedforeachracial
group. The improvement in survival across the diagnostic
eras was also seen uniformly in all subtypes. The 5-year
RSR for NLP HL was 71.5% for patients diagnosed in the
years 1973–79; 91.8% (1980–89); 91.5% (1990–99); 98.9%
(2000–07). Those for NS HL were 80.1% (1973–79); 84.2%
(1980–89); 88% (1990–99); 89.9% (2000–07). Kaplan-Meier
survival curves also show a signiﬁcant diﬀerence in survival6 Advances in Hematology
Table 2: Racial diﬀerences in the presentation of Hodgkin lymphoma.
Characteristic White Black A/PI P-value
Count % Count % Count % W versus B W versus A/PI
n 14,076 1,693 722
Age, years
Mean 42 38 38 <.001 <.001
Interquartile Range 26–57 25–49 23–51
<45 8,472 60.19 1,148 67.81 493 68.28 <.001 <.001
≥45 5,604 39.81 545 32.19 229 31.72
Male sex 7,711 54.78 913 53.93 399 55.26 .51 .80
Stage
I 2,717 19.30 360 21.26 95 13.16 <.001 <.001
II 5,555 39.46 527 31.13 327 45.29
III 2,639 18.74 365 21.56 133 18.42
IV 2,349 16.69 356 21.03 128 17.73
Unknown 816 5.80 85 5.02 39 5.40
Extranodal disease
Yes 3,170 22.52 455 26.88 179 24.79 <.001 .17
No 10,090 71.68 1,153 68.10 504 69.81
Unknown 816 5.80 85 5.02 39 5.40
Bs y m p t o m s
Yes 4,988 35.44 608 35.91 305 42.24 .06 .60
No 5,783 41.08 629 37.15 275 38.09
Unknown 3,305 23.48 456 26.93 142 19.67
Note: for each variable, cases with unknown information were excluded in calculating the P-value.
Abbreviations: W: whites; B: blacks; O: others.
by age at diagnosis, with patients who were ≥45 years having
a worse outcome (log-rank test P<. 001). Across histologic
subtypes, survival for patients with NLP HL was better
than that for patients with CHL (log-rank test P<. 001;
Figure 3(d)). Although stage of disease did aﬀect survival
outcomes, age ≥45 years had a greater impact on survival
(Figure 3(b)).
4. Discussion
Our study examines incidence, presentation, and survival
of HL with respect to previously assessed risk factors: age,
gender, race, stage, and histologic subtype. Although these
riskfactorshavebeenexaminedinpriorstudies,themajority
of these studies focused on one factor independent of
the others. Using the most recent national SEER data, we
analyzed the relationships between patient demographics,
presentation of disease, and overall survival in an attempt
to identify which risk factors had the most inﬂuence on
incidence and survival for HL.
Lack of central pathology review is a limitation of this
and all other SEER studies. In our study cohort, patients
included were diagnosed with HL based on local healthcare
system standards. Another possible limitation of this analysis
is the use of cases classiﬁed according to ICD-O-2, prior to
the introduction of the revised WHO classiﬁcation in 2001.
Clarke et al. studied the reliability of computer-converted
ICD-O-2 codes to ICD-O-3 codes in SEER and found that
the agreement for classical HL was 95% while that for
nodular HL was 44% [19, 27].
In the current analyses, we categorize racial groups into
white, black, AI/AN, and A/PI. It should be noted, however,
that clumping all Asians together might not be meaningful
for detailed epidemiologic studies since it lumps together
genetically distinct and heterogenous populations of patients
who would likely have diﬀerent genetic, dietary, and possibly
environmental risks for lymphoma. Although the SEER data
provide detailed information on race at the case level, it
classiﬁes race into white, black, AI/AN, and A/PI at the
populationlevel;therebyprecludingfurtheranalysesofracial
subgroups with this dataset. Another limitation of the SEER
data is the absence of information on the HIV status of the
patients. This precludes that analysis of incidence of HIV-
positive patients across racial groups.
4.1. Incidence. As expected, HL incidence was higher in
males than females and higher in whites than other races.
These data also address the debate over the existence of a
bimodal incidence pattern for HL with current population-
based data. As Figure 2 displays, there are clear CHL
incidence peaks for young adults and individuals ≥70 years
of age for both genders and all racial groups except for blackAdvances in Hematology 7
Table 3: Cox regression models of predictors mortality among Hodgkin lymphoma patients.
Factors Univariate model Multiple variable model
Hazard ratio 95% CI Hazard ratio 95% CI
Age, years
<45 1.00 1.00
≥45 5.08 4.86 5.31 4.82 4.40 5.29
Gender
Female 1.00 1.00
Male 1.32 1.27 1.38 1.17 1.07 1.28
Race
White 1.00 1.00
Black 1.19 1.11 1.28 1.54 1.35 1.76
Asian/PI 1.11 0.97 1.26 1.09 0.86 1.37
AI/AN 1.32 0.87 2.01 0.83 0.39 1.74
Disease stage
I/III 1.00 1.00
IV 2.45 2.26 2.65 1.29 1.05 1.59
Extranodal disease
No 1.00 1.00
Yes 2.17 2.01 2.34 1.10 0.91 1.34
Bs y m p t o m s
No 1.00 1.00
Yes 2.20 2.01 2.40 1.82 1.66 2.00
HL subtype
NS HL 1.00 1.00
LR HL 1.29 1.15 1.44 1.10 0.86 1.40
MC HL 1.99 1.89 2.09 1.31 1.17 1.46
LD HL 4.08 3.71 4.48 2.02 1.58 2.57
CHL, NOS 2.17 2.04 2.30 1.65 1.46 1.86
NLP HL 0.74 0.60 0.91 0.71 0.52 0.98
males, where the peaks are not nearly as prominent. While
a bimodal incidence pattern of HL is largely debated, these
ﬁndings are consistent with several other studies [28–30].
In terms of race, both blacks and Asian/Paciﬁc Islanders
had lower incidence rates than whites for CHL. Asians
had signiﬁcantly lower incidence rates for virtually all HL
subtypes. Internationally, Asians have lower HL incidence
than other races. According to Glaser and Hsu, consistently
low incidence rates of HL in the Asian population as a
whole suggest genetic resistance, possibly related to HLA
type, and diﬀerences between US-born and native Asian
groups suggest environmental inﬂuences [6]. HLA type
has been shown to aﬀect EBV-related HL incidence, and
EBV-positive HL is most common in the Asian population
[31, 32]. Though its impact seems dependent on age, early
microbiome exposure has been linked to having a protective
eﬀectagainstHL[33,34].Racialdiﬀerencesinearlyexposure
to viral pathogens and microbiomes may inﬂuence these
diﬀerences in the incidence of HL and the patterns of HL
presentation discussed below. For most HL subtypes, black
race was associated with lower HL incidence rates. However,
for NLP HL, blacks had a signiﬁcantly higher incidence rate
than whites. This is somewhat surprising given that NLP
HL has a clinical behavior similar to indolent non-Hodgkin
lymphomas (NHLs), and black Americans also have lower
incidence of NHL [35]. Further studies investigating the
etiology of racial diﬀerences in incidence patterns for HL
using admixture mapping will help to elucidate genetic
susceptibility and gene-environment interaction associated
with the incidence of HL and HL subtypes.
4.2. Presentation. We found signiﬁcant diﬀerences in the
clinical features at presentation across the racial groups stud-
ied. These diﬀerences may contribute to racial diﬀerences
in survival since age of onset, stage, and B-symptoms at
diagnosis are known prognostic factors for HL. Not only
did blacks and Asian/PI present at a lower age than whites
(38 versus 42 years), but both groups also had a higher
percentage of patients with stage III/IV disease. Additionally,
blacks had a higher percentage of patients presenting with
an extranodal disease. One possible explanation for these8 Advances in Hematology
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Figure 3: Kaplan-Meier Survival Curves of HL Patients. (a) Survival curves by race. (b) Survival curves by age at diagnosis (<45 versus ≥45
years) and stage (Stage I-IIA versus Stage IIB-IV). (c) Survival curves by era of diagnosis. (d) Survival curves for CHL and NLP HL.
diﬀerences in presentation could be racial diﬀerences in the
prevalence of human immunodeﬁciency virus (HIV) among
individuals with HL. HIV-positive HL patients present at a
moreadvanced stagewithassociated extranodal involvement
and B symptoms [36]. Biggar et al. found that individuals
with HIV/AIDS were also more likely than the general pop-
ulation to be diagnosed with HL. AIDS cases with moderate
immunosuppression (225–249 CD4 cells/μLa to n s e t )w e r e
estimated to have a 15-fold increased risk of HL [37]. In
Glaser’s HIV related HL study, 21.3% of blacks in the study
were HIV positive, whereas only 13% of whites and 2.3% of
AsianswereHIV-positive[36].Onanationalscale,blacksare
signiﬁcantly overrepresented in HIV/AIDS incidence [38].
Patients of nonwhite race were diagnosed earlier and with a
higher level of disease progression. Recent epidemiological
studies in NHL also found signiﬁcant diﬀerences between
blacks and whites in the age of presentation and racial
diﬀerences in overall survival [35, 39–41].
4.3. Survival. Age, gender, presenting symptoms, stage, and
race were all predictors of survival according to our multiple
variable Cox regression. The international prognostic score
for advance stage HL identiﬁed seven factors with similar
independentprognosticeﬀects:serumalbuminlevel<4gper
deciliter, hemoglobin level <10.5g per deciliter, male sex, an
age of ≥45 years, stage IV disease, white-cell count >15,000
per cubic millimeter, and lymphocyte count <600 per cubic
millimeter, <8% of the white-cell count, or both [42]. In
this population-based analysis, age of 45 or above, stage IV
disease, and male gender remained signiﬁcant predictors of
HL survival for patients with advanced stage disease (data
not shown) and all patients. The remaining components of
the prognostic score are laboratory based and therefore not
able to be analyzed with SEER.
Our data showed that an age of 45 or older had an
overwhelming association with mortality (HR 5.25). The
next highest predictor was the presence of B symptoms (HR
1.90), followed by black race (HR 1.54). Only after these
factorsdidstageIVdisease(HR1.39)andmalegender(1.19)
come into play. Age was signiﬁcantly more predictive of
survival than stage (Figure 3(b)). Interestingly enough, both
race and B-symptoms at presentation also were signiﬁcant
predictors of survival in multiple variable regression models.Advances in Hematology 9
Determining whether the impact of race and B-symptoms
are confounded by diﬀerences in the prevalence of HIV or
EBV in these groups needs to be addressed with additional
studies, since both viruses can inﬂuence the incidence and
survival of HL [34, 36].
As mentioned previously, black individuals also have a
higher incidence than whites of NLP HL. Using NS as a
reference, MC, LD, and CHL NOS subtype diagnoses were
predictive of worse 5-year survival (Table 3). Cox regression
modelsshowedthatNLPwastheonlysubtypethatpredicted
for better survival than NS (Table 3), and the overall survival
curve (Figure 3(d)) suggests that while NLP HL may have
worse initial outcomes, long-term survival is better for NLP
HL patients than for CHL patients. It should however be
noted while interpreting these survival analyses that there
might be potential misdiagnosis of NLP HL as T-cell-
rich B-cell lymphoma or follicular lymphoma. Additional
HL subtype-speciﬁc studies are needed to investigate fac-
tors that inﬂuence outcomes particularly with the future
development of individualized treatment strategies for HL
subtypes.
Finally, the survival curves in Figure 3(c) demonstrate
that the survival probability continues to improve for
patients with HL across eras of diagnosis. This is particularly
interesting sinceinthe1980s thecombinationchemotherapy
regimen of doxorubicin, bleomycin, vinblastine, and dacar-
bazine (ABVD) supplanted previous treatment strategies
such as radiation therapy alone and nitrogen mustard,
vincristine, procarbazine, and prednisone (MOPP) and
has remained the standard of care for HL ever since
[43–49]. However, despite the commonplace use of this
regimen across most of the eras studied, HL survival has
serially improved. We speculate that an increase in the
access to care, improvement of diagnostic tools such as
computed tomography and positron emission tomography
scans, and eﬃcacy of supportive care may be responsible
for these increases in survival. A Spanish study found that
patients treated before 1980 were 3.5 times more likely
to die of infection and 7.1 times more likely to die of
toxicity than those treated after 1980 [50]. Another reason
for the improved survival in recent years could be due
to improved diagnostic accuracy and elimination of the
misdiagnosis of HL cases as NHL in the earlier years. The
greatest additional improvements in HL survival are likely to
come from identifying poor risk subgroups and developing
management approaches speciﬁc for these populations that
do not beneﬁt from standard therapy. Studies such as this
one help to identify subgroups (black patients, patients 45
years or older, and patients with stage IV disease) where
speciﬁc interventions such as improving access to care,
adding biological therapies, and intensifying initial therapy
may be explored to improve survival for these poor-risk
populations.
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